NCT07239479

Brief Summary

This randomized double-blind controlled clinical trial aims to evaluate the efficacy and safety of combining Dexmedetomidine with Desflurane in patients undergoing elective laparoscopic colectomy. The study will assess whether the combination can reduce Desflurane consumption, improve intraoperative hemodynamic stability, and enhance postoperative recovery compared to Desflurane alone.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
9mo left

Started Dec 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Dec 2025Jan 2027

First Submitted

Initial submission to the registry

November 16, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 20, 2025

Completed
11 days until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2027

Last Updated

December 30, 2025

Status Verified

November 1, 2025

Enrollment Period

1.1 years

First QC Date

November 16, 2025

Last Update Submit

December 28, 2025

Conditions

Colorectal Neoplasms

Keywords

DexmedetomidineDesfluraneGeneral anesthesiaColorectal surgeryERASHemodynamic stability

Outcome Measures

Primary Outcomes (1)

  • Average Desflurane consumption per hour (mL/h) during surgery.

    Average Desflurane consumption per hour (mL/h) during surgery.

    During surgery

Study Arms (2)

Intervention Group

EXPERIMENTAL

Arm 1 - Dexmedetomidine + Desflurane (Intervention Group): Dexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery. Desflurane administered at 1 MAC with EtControl mode.

Drug: Dexmedetomidine + Desflurane

Control Group

PLACEBO COMPARATOR

Arm 2 - Desflurane + Normal Saline (Control Group): Normal saline infusion with identical timing and volume as the intervention group. Desflurane administered at 1 MAC with EtControl mode

Drug: Desflurane + Normal Saline

Interventions

Dexmedetomidine + DesfluraneDRUG

Dexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery. Desflurane administered at 1 MAC with EtControl mode.

Intervention Group
Desflurane + Normal SalineDRUG

Normal saline infusion with identical timing and volume as the intervention group. Desflurane administered at 1 MAC with EtControl mode.

Control Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-65 years
  • ASA Physical Status I-II
  • Elective laparoscopic colectomy
  • Written informed consent provided

You may not qualify if:

  • Severe cardiac, hepatic, or renal disease
  • COPD or bronchial asthma
  • Chronic opioid or psychotropic medication use
  • Atrioventricular block (grade II-III), sick sinus syndrome
  • Significant intraoperative bleeding or hemodynamic instability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tam Anh TP. Ho Chi Minh General Hospital

Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

DexmedetomidineDesfluraneSaline Solution

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsEthyl EthersEthersOrganic ChemicalsMethyl EthersHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Central Study Contacts

Phan Quoc Thai, MD

CONTACT

+84 964 152 360thaipq@tahospital.vn

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 16, 2025

First Posted

November 20, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 30, 2027

Last Updated

December 30, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Individual patient data (IPD) will remain confidential. Aggregated, de-identified data may be shared upon reasonable request after study completion for academic purposes.

Locations

VN(1)